Celgene to buy Gloucester Pharmaceuticals, another company with a focus on developing drugs for blood cancer. I really like Celgene’s laser-like focus in its product portfolio – very smart.
Keep those new blood thinners coming.
AstraZeneca‘s Seroquel gets an expanded label for Major Depressive Disorder (add-on treatment).
Folotyn: 30K/month cancer treatment?? Wow (from NY Times).
The race for the new oral MS drug approval – did Novartis just take the lead?
RECOMMENDED
Medical Device Training. The Impactiviti network of providers has what you need. Contact us (stevew at impactiviti dot com, or phone at 973-947-7429) for recommendations.
PLUS
Pharma: Socializing in a Straitjacket? A somewhat shallow brushstroke in AdWeek about pharma and social media. AND – only TWO FDA inspectors in all of China (where much drug manufacturing is moving)? I bet that gets changed fast!
JUST FOR FUN
———-
Subscribe to the Impactiviti blog via e-mail (which will bring you Impactiviti Daily – a brief of the day’s top pharma news)
Sign up for the Impactiviti Connection twice-monthly e-newsletter (see sample)
Connect with Steve Woodruff
Leave a Reply